Nueronal death due to apoptosis in Parkinson's disease;La mort neuronale par apoptose dans la maladie de Parkinson

Revue Neurologique

Volumn 153, Issue 8-9, 1997, Pages 499-508

  Ruberg, M ^a   France Lanord, V ^a   Brugg, B ^a   Lambeng, N ^a   Michel, P P ^a   Anglade, P ^a   Hunot, S ^a   Damier, P ^a   Faucheux, B ^a   Hirsch, E ^a   Agid, Y ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; ARTICLE; CHOLINERGIC NERVE; DOPAMINERGIC NERVE CELL; HUMAN; NERVE CELL DEGENERATION; NORADRENERGIC NERVE; OXIDATIVE STRESS; PARKINSON DISEASE; SEROTONINERGIC NERVE;

APOPTOSIS; FREE RADICALS; HUMANS; NEURONS; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 9844260068     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. AGID Y., GRAYBIEL A.M., RUBERG M., HIRSCH E., BLIN J., DUBOIS B., JAVOY-AGID F. (1990a). The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role? In Streisser M.B., Korczyn A.D., Melamed E., Youdim M.B.H. (eds), Advances in Neurology, vol. 53: Parkinson's disease: Anatomy Pathology and Therapy, pp.83-100. Raven Press. New York.
2. AGID Y., GRAYBIEL A., RUBERG M., HIRSCH E., BRANDEL J.P., CERVERA P., JUNCOS J., LEHÉRICY S., MALESSA S., RANSMAYER G., JAVOY-AGID F. (1990b). In Nagatsu T., Risher A., Yoshida M. (eds), Basic, Clinical and Therapeutic Aspects of Alzheimer and Parkinson's diseases, vol. 1, pp. 427-444. Plenum Press, New York.
3. AGID Y., RUBERG M., JAVOY-AGID F., HIRSCH E., RAISMAN-VOZARI R., VYAS S., FAUCHEUX B., MICHEL P., KASTNER A., BLANCHARD V., DAMIER P., VILLARES J., ZHANG P. (1993). Are dopaminergic neurons selectively vulnerable to Parkinson's disease? In : Narabayashi H., Nagatsu T., Yanagisawa N., Mizuno Y. (eds). Advances in Neurology, vol. 60 : Parkinson's Disease : from basic research to treatment, pp. 148-164. Raven Press, New York.
4. AGID Y., RUBERG M., RAISMAN R., HIRSCH E., JAVOY-AGID F. (1990c). The biochemistry of Parkinson's disease. In Stern G. (ed), Parkinson Disease, pp. 99-125. Chapman Hall, London.
5. AMBANI L.M., VAN WOERT M.H., MURPHY S. (1975). Peroxidase and catalase activities were determined in various regions of parkinsonian brains and control brains from patients with non neurological diseases. Arch Neuron, 32 : 114-118.
6. ANGLADE P., VYAS S., JAVOY-AGID F., HERRERO M.T., MICHEL P.P., MARQUEZ J., MOUATT-PRIGENT, RUBERG M., HIRSCH E.G., AGID Y. (1997). Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopatol, 12 : 25-31.
7. BARTFAI T., SCHULTZBERG M. (1993). Cytokines in neuronal cell types. Neurochem Int, 22 : 435-444.
8. BEAL M.F. (1995). Mitochondrial Function and Oxidative Damage in Neurodegenerative Diseases. RG Landes, Austin.
9. BOKA G., ANGLADE P., WALLACH D., JAVOY-AGID F., AGID Y., HIRSCH E.C. (1994). Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett, 172 : 151-154.
10. BRUGG B., MICHEL P.P., AGIO Y., RUBERG M. (1996). Ceramide induces apoptosis in cultured mesencephalic neurons. J Neurochem, 66 : 733-739.
11. BUTLER B., VAN HUFFEL C. (1994). Unraveling function in the TNF ligand and receptor families. Science, 264 : 667-668.
12. CALNE D. (1992). The free radical hypothesis in Parkinson's disease : evidence aginst it. Ann Neurol, 32 : 799-803.
13. CADENAS E., BOVERIS A., RAGAN C.I., STOPPAM A.O. (1977). Production of Superoxide radicals and hydrogen peroxide by NADH-ubiquinone reductase and ubiquinol-cytochrome c reductase from beef-heart mitochondria. Arch Biochem Biophys, 180 : 248-257.
14. CLEETER M.W.J., COOPER J.M., SCHAPIRA A.H.V. (1992). Irreversible inhibition of mitochondrial complex 1 by 1-methyl-4-pyridinium: evidence for free radical involvement. J Neurochem, 58 : 186-189.
15. DAHLSTROM A., WIGANDER A., LUNDMARK K., GOTTFRIES C.G., CARVEY P.M., McRAE A. (1990). Investigations on auto-antibodies in Alzheimer's and Parkinson's diseases, using defined neuronal cultures. J Neural Transm Suppl, 29 : 195-206.
16. DAHLSTROM A., FUXE K. (1964). Evidence for the existence of monoamine-containing neurons in the mammalian nervous system. 1. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand (Suppl. 232), 62 : 1-55.
17. DAMIER P., HIRSCH E.C., ZHANG P., AGID Y., JAVOY-AGID F. (1993). Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience, 52 : 1-6.
18. DEXTER D.T., WELLS F.R., AGID F., LEES A.J., JENNER P., MARSDEN C.D. (1987). Increased nigral iron content in postmortem parkinsonian brain. Lancet, 2 : 1219-1220.
19. DEXTER D.T., WELLS F.R., AGID F., AGID Y., LEES A., JENNER P., MARSDEN C.D. (1989). Increased iron nigral content and alteration in other metals occuring in Parkinson's disease. J Neurochem, 52 : 1830-1836.
20. DEXTER D.T., CARAYON A., JAVOY-AGID F., AGID Y., WELLS F.R., DANIEL S.E., LEES A.J., JENNER P., MARSDEN C.D. (1991). Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other degenerative diseases affecting the basal ganglia. Brain, 114 : 1953-1975.
21. DEXTER D.T., CARTER C.J., WELLS F.R., JAVOY-AGID F., AGID Y., LEES A., JENNER P., MARSDEN C.D. (1989). Basal lipid peroxidation is increased in Parkinson's disease. J Neurochem, 52 : 381-389.
22. DEXTER D.T., HOLLEY A.E., FLITTER W.D., SLATER T.F., WELLS F.R., DANIEL S.E., LEES A.J., JENNER P., MARSDEN C.D. (1994). Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra : an HPLC and ESR study. Mov Dis, 9 : 92-97.
23. DUBOIS B., PILLON B. (1995). Do cognitive changes of Parkinson's disease result from dopamine depletion? J Neural Transm, Suppl 45 : 27-34.
24. DUVOISIN R.C. (1982). The cause of Parkinson's disease. In Marsden C.D., Fahn S. (eds), Movement Disorders, pp. 8-24. Butterworth Scientific, London.
25. ERNSTER L., DALLNER G., AZZONE G.F. (1963). Differential effects of rotenone and amytal on mitochondrial electron and energy transfer. J Biol Chem, 238 : 1124-1130.
26. FAHN S. AND COHEN G. (1992). The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol, 32 : 804-812.
27. FAUCHEUX B., NILLESSE N., DAMIER P., SPIK G., MOUATT-PRIGENT A., PIERCE A., LEVEUGLE B., KUBIS N., HAUW J.J., AGID Y., HIRSCH E. (1995). Expression of lactoferrin receptors is increased in the mesencepnalon of patients with Parkinson disease. Proc Natl Acad Sci (USA) 92 : 9603-9607.
28. FEARNLEY J.M., LEES A.J. (1991). Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain, 114 : 2283-2301.
29. GREENE L.A., TISCHLER A.S. (1976). Establishment of a nor-adrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci (USA) 73 : 2424-2428.
30. GREENLUND L.J.S. AND DECKWERTH T.L. AND JOHNSON JR E.M. (1995). Superoxide dimsutase delays neuronal apoptosis: a role for reactive oxygen species in programmed neuronal death. Neuron, 14 : 303-315.
31. GUNSEKAR P.G., KANTHASAMY A.G., BOROWITZ J.L. AND ISOM G.E. (1995). NMDA receptor activation produces concurrent generation of nitric oxide and reactive oxygen species: implication for cell death. J Neurochem, 65 : 2016-2021.
32. HATTORI N., TANAKA M., OZAWA T., MIZUNO Y. (1991). Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease. Ann Neurol, 30 : 563-571.
33. HENNET T., RICHTER C. AND PETERHANS E. (1993). Tumor necrosis factor-α induces Superoxide anion generation in mitochondria of L929 cells. Biochem J, 289 : 587-592.
34. HIRSCH E.C. (1992). Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease. Ann Neurol, 32 : S88-S93.
35. HIRSCH E.C. (1993). Does oxidative stress participate in nerve cell death in Parkinson's disease. Eur Neurol (suppl 1) : 52-59.
36. HIRSCH E.C. (1994). Nerve cell death in Parkinson's disease. In Nappi G., Carceni T., Martignoni E., Giovannini P (eds), New Advances in Parkinson Disease and Other Extrapyramidal Disorders, pp. 7-14, Smith Gordon, London.
37. HIRSCH E.C., GRAYBIEL A.M., AGID Y. (1988). Melanized dopaminergic neurons are differentially affected in Parkinson's disease. Nature, 334 : 345-348.
38. HIRSCH E.C., BRANDEL J.P., GALLE P., JAVOY-AGID F., AGID Y. (1991). Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an x-ray microanalysis. J Neurochem, 56 : 446-451.
39. HORNYKIEWICZ O. (1982). Parkinson's disease. In Crow T.J (ed.), Disorders of Neurohumoral Transmission, pp. 121-143. Academic Press, London.
40. JACQUE C., TCHÉLINGÉRIAN J.L. (1994). Nouveaux concepts sur le rôle des cytokines dans le système nerveux central. Rev Neurol, 150 : 748-756.
41. JANETSKY B., HAUCK S., YOUDIM M.B.H., RIEDERER P., JELLINGER K., PANTUCEK F., ZÖCHLING R., BOISSL K.W., REICHMANN H. (1994). Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett, 169 : 126-128.
42. JENNER P. (1994). Oxidative damage in neurodegenerative disease. Lancet, 344 : 796-798.
43. KOLESNICK R., GOLDE D.W. (1994). The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell, 77 : 325-328.
44. KOLESNICK R.N., HAIMOWITZ-FRIEDMAN A., FUKS Z. (1994). The sphinogomyelin signal transduction pathway mediates apoptosis for tumor necrosis factor, Fas, and ionizing radiation. Biochem Cell Biol, 72 : 471-474.
45. KOLESNICK R., GOLDE D.W. (1994). The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell, 77 : 325-328.
46. LANGSTON J.W. (1989). Mechanisms underlying neuronal degeneration in Parkinson's disease : an experimental and theoretical treatise. Mov Dis 4 (suppl 1) : S15-S25.
47. LANGSTON J.W., IRWIN I., RICAURTE G.A. (1987). Neurotoxins, parkinsonism and Parkinson's disease. Pharm Ther, 32 : 19-49.
48. LIPTON S.A. (1994). Neuronal injury associated with HIV-1 and potential treatment with calcium-channel and NMDA antagonists. Mol Neurobiol, 8 : 181-196.
49. LOSCHEN G., AZZI A., RICHTER C., FLOHE L. (1974). Superoxide radicals as precursors of mitochondrial hydrogen peroxide. FEBS Lett, 42 : 68-72.
50. MANN V.M., COOPER J.M., KRIGE D., DANIEL S.E., SCHAPIRA A.H., MARSDEN C.D. (1992). Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain, 115 : 333-342.
51. MARTTILA R.J., LORENTZ H., RINNE U.K. (1988). Oxygen toxicity protecting enzymes in Parkinson's disease : increase of Superoxide dismutase-like activity in the substantia nigra and basal ganglia. J Neurol Sci, 86 : 321-331.
52. MARTTILA R.J., RINNE U.K., TIILIKAINEN A. (1982). Virus antibodies in Parkinson's disease. Herpes simplex and measles virus antibodies in serum and CSF and their relation to HLA types. J Neurol Sci, 54 : 227-238.
53. MATSUYAMA T., HATA R., TAGAYA M., YAMAMOTO Y., NAKAJIMA T., FURUYAMA J., WANAKA A., SUGITA M. (1994). Fas antigen mRNA induction in postischemic murine brain. Brain Res, 657 : 342-346.
54. 2+ concentration, and neurotoxicity and increase antioxidant enzyme activaties in hippocampal neurons. J Neurochem, 65 : 1740-1751.
55. MCGEER P.L., ITAGAKI A., AKIYAMA H., MCGEER E.G. (1988). Rate of cell ceath in parkinsonism indicates active neuropathological process. Ann Neurol, 24 : 564-576.
56. MICHEL P.P., DANDAPANI B.K., KNUSEL B., SANCHEZ-RAMAS J., HEFTI F. (1990). Toxicity of 1-methyl-4-phenylpyridinium for rat dopaminergic neurons in culture : selectivity and irreversibility. J Neurochem, 54 : 1102-1110.
57. MICHEL P.P., AGID Y. (1995). Synergistic differentiation by chronic exposure to cyclic AMP and nerve growth factor renders rat phaeochromocytoma PC12 cells totally dependent upon trophic support for survival. Eur J Neurosci, 7 : 251-260.
58. MIURA M., ZHU H., ROTELLO R., HARTWIEG E.A., YUAN J. (1993). Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell, 75 : 653-660.
59. MONTAGNIER L., OLIVIER R., PASQUIER C. (1997). Stress Oxidatif and Redox Regulation. Marcel Dekker, New York.
60. NAGATA S., GOLSTEIN P. (1995). The Fas death factor. Science, 267: 1449-1456.
61. NISHIMURA T., AKIYAMA H., YONEHARA S., KONDO H., IKEDA K., KATO M., ISEKI E., KOSAKA K. (1995). Fas antigen expression in brains of patients with Alzheimer-type dementia. Brain Res, 695 : 137-145.
62. PERRY T.L., GODIN D.V., HANSEN S. (1982). Parkinson's disease: A disorder due to nigral glutathione deficiency? Neurosci Lett, 33 : 305-310.
63. RABIZADEH S., OH J., ZHONG L.T., YANG J., BITLER L.L., BREDESEN D.E. (1993). Induction of apoptosis by the low-affinity NGF receptor. Science, 261 : 345-348.
64. RIEDERER P., SOFIC E.M., RAUSCH W.D., SCHMIDT B., REYNOLDS G.P., JELLINGER K., YOUDIM M.B.H. (1989). Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J Neurochem, 52 : 515-520.
65. RIVAS C.I., GOLDE D.W., VERA J.C., KOLESNICK R.N. (1994). Involvement of the sphingomyelin pathway in autocrine tumor necrosis factor signaling for human immunodeficiency virus production in chronically infected HL-60 cells. Blood, 83 : 2191-2197.
66. ROSSOR M.N. (1981). Parkinson's disease and Alzheimer's disease as disorders of the isodendritic core. Br Med J, 283 : 1588-1590.
67. RUBERG M., FRANCE-LANORD V., BRUGG B., HUNOT S., ANGLADE P., DAMIER P., FAUCHEUX B., AGID Y. (1997). Parkinson's disease, apoptosis and oxidative stress. In Montaignier L., Olivier R., Pasquier C. (eds), Stress Oxidatif and Redox Regulation, pp. 473-487. Marcel Dekker, New York.
68. SAGGU H., COOKSEY J., DEXTER D., WELLS F.R., LEES A., JENNER P., MARSDEN C.D. (1989). A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem, 53 : 692-697.
69. SCHERMAN D., DESNOS C., DARCHEN F., POLLAK, JAVOY-AGID F., AGID Y. (1989). Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol, 26 : 551-557.
70. SCHAPIRA A.H.V. (1995). Nuclear and mitochondrial genetics in Parkinson's disease. J Med Genet, 32 : 411-415.
71. SCHAPIHA A.H.V., COOPER J.M., DEXTER D., CLARK J.B., JENNER P., MARDEN C.D (1990a). Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem, 54 : 823-827.
72. SCHAPIRA A.H.V., MANN V.M., COOPER J.M., DEXTER D., DANIEL S.E., JENNER P., CLARKE J.B., MARSDEN C.D (1990b). Anatomic and disease specificity of NADH CoQ reductase (complex I) deficiency in Parkinson's disease. J Neurochem, 55 : 2142-2145.
73. SCHULZE-OSTHOFF K., BAKKER A.C., VANHAESEBROECK B., BEYAERT R., JACOBS W.A. AND FIERS W. (1992). Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. J Biol Chem, 267 : 5317-5323.
74. SCHULZE-OSTHOFF K., BEYAERT R., VANDEVOORDE V., HAEGEMAN G., FIERS W. (1993). Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF. EMBO J, 12 : 3095-3104.
75. SIAN J., DEXTER D.T., LEES A.J., DANIEL S., JENNER P., MARSDEN C.D. (1994). Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol, 36 : 356-361.
76. SOFIC E., LANGE K.W., JELLINGER K., RIEDERER P. (1992). Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett, 142 : 128-130.
77. SOFIC E., PAULUS W., JELLINGER K., RIEDERER P., YOUDIM M.B.H. (1991). Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem, 56 : 978-982.
78. SOFIC E., RIEDERER P., HEINSEN H., BECKMAN H., REYNOLDS G.P., HEBENSTREIT G., YOUDIM M.B.H. (1988). Increased iron (III) and total iron content in post-mortem substantia nigra of parkinsonian brain. J Neural Transm, 74 : 199-205.
79. VAYSSIERE J.L., PETIT P.X., RISLER Y. AND MIGNOTTE B. (1994). Commitment to apoptosis is associated with changes in mitochondrial biogenesis and activity in cell lines conditionally immortalized with simian virus 40. Proc Natl Acad Sci (USA), 91 : 11752-11756.
80. WESTENDORP M.O., SHATROV V.A., SCHULZE-OSTHOFF K., FRANK R., KRAFT M., Los M., KRAMMER P.H., DROGE W., LEHMANN V. (1995). HIV-1 Tat potentiates TNF-induced NF kappa B activation and cytotoxicity by altering the cellular redox state. EMBO J, 14 : 546-554.
81. WYLLIE A.H., MORRIS R.G., SMITH A.L., DUNLOP D. (1984). Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol, 142 : 67-77.
82. YORITAKA A., HATTORI N., UCHIDA K., TANAKA M., STADTMAN, MIZUNO Y. (1996). Immunohistochemical detection of 4-hydroxynoneal protein adducts in Parkinson disease. Proc Natl Acad Sci (USA), 93 : 2696-2701.
83. ZHANG P., DAMIER P., HIRSCH E.G., AGID I., CEBALLOS-PICOT, SINET P.M., NICOLE A., LAURENT M., JAVOY-AGID F. (1993). Preferential expression of Superoxide dismutase messenger RNA in melanized neurons in human mesencephalon. Neuroscience, 55 : 167-175.